It is currently Sun Jun 26, 2016 3:48 pm

News News of Tysabri (Antegren or Natalizumab)

Site map of Tysabri (Antegren or Natalizumab) » Forum : Tysabri (Antegren or Natalizumab)

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

PML Cases Now Reach 448

The number of Tysabri related PML cases has increased by 9 over the previous month, bringing the new total to 438. It isn't known if there are any deaths included in this figure.

These are the cases reported by Biogen and may not reflect the real number of PML cases encountered by MS patients using Tysabri.
Read more : PML Cases Now Reach 448 | Views : 1201 | Replies : 0

No definite melanoma link for Tysabi...

Australian regulator finds no definite melanoma link for Tysabri

Australia’s Therapeutic Goods Administration (TGA) revealed today that it is monitoring reports of melanoma in patients being treated with natalizumab and encourages consumers and health professionals to report all such cases....... Read More -
Read more : No definite melanoma link for Tysabi... | Views : 1131 | Replies : 1

Tysabri is a dangerous drug

Brief background, I used to work in the FDA program that handled drugs monitored under the Risk Evaluation and Mitigation Strategy program. The FDA requires that if a death (or adverse event) arises from the drug, it must be reported. BUT, they do not require the drug companies to proactively obtain that information. So the only way we recorded death info is if the doctor causally calls about ordering forms, and just so happens to ...
Read more : Tysabri is a dangerous drug | Views : 2703 | Replies : 5

PML Cases now reach 439!

Last month the number of Biogen reported Tysabri related cases jumped by 9 making the new total 439. Don't know if any more deaths are included in this number. Unfortunately, it just isn't getting any better.
Read more : PML Cases now reach 439! | Views : 1309 | Replies : 7

Efficacy and safety of natalizumab in multiple sclerosis

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results


BACKGROUND: Clinical trials established the efficacy and safety of natalizumab. Data are needed over longer periods of time and in the clinical practice setting..... Read More -
Read more : Efficacy and safety of natalizumab in multiple sclerosis | Views : 1224 | Replies : 5

HIV drug may help in PML

A relatively simple way to make progressive multifocal leukoencephalopathy (PML) more survivable appears to have worked in a multiple sclerosis patient taking natalizumab (Tysabri)....... Read More -
Read more : HIV drug may help in PML | Views : 1149 | Replies : 1

PML cases now reach 430

Latest "reported" cases of PML has risen by 7 last month to 430. Not known if any more related deaths.
Read more : PML cases now reach 430 | Views : 1582 | Replies : 13

PML cases now reach 423

PML cases have jumped 5 more from last month...up to 523. Not known if any additional deaths took place.
Read more : PML cases now reach 423 | Views : 1259 | Replies : 4


I'm new to the forum but I'm currently on tecfidera and have been on it for 4 months. I was on Gilenya and didn't have any relapses but decided to change after a year because of hair loss and headaches. As soon as I came off Gilenya I had major relapse transitioning to tecfidera. It took me almost two months to recover from this last relapse. I regret coming off Gilenya now but my Doc ...
Read more : Rebound | Views : 1150 | Replies : 2

Tysabri to start soon......

My neuro wants me to start Tysabri. I have done all kinds of research and read on this page. My thoughts have been scrambled on this issue for days. I just had JC bloodtests. He said his paitents both JC + and - are on it. I've Bernard on Copaxone, tecfidera and avonex and been sicker to different degrees on them. Life is too short to be sick 5 out of 7 days a week. ...
Read more : Tysabri to start soon...... | Views : 1841 | Replies : 13


Login  •  Register


Total posts 232931 • Total topics 24943 • Total members 16081

Contact us | Terms of Service